T he cholesterol content of atherosclerotic plaques is derived from circulating low density lipoproteins (LDLs) in plasma. Along with cholesterol, apolipoprotein (apo) B also accumulates in the atherosclerotic plaque. 1 Receptors specific for lipoproteins have been identified on a variety of circulating 23 and tissue-fixed 4 -6 cells. These LDL receptors are specific for lipoproteins containing either apoB or apoE. Abundant epidemiological data strongly support an atherogenic role for the apoB-100-containing lipoproteins (LDL, intermediate density lipoprotein, and very low density lipoprotein [VLDL] ) and an antiatherogenic role for high density lipoprotein (HDL). 78 Mutation in the LDL receptor gene is believed to be the cause for familial hypercholesterolemia (FH), either heterozygous or homozygous. 9 As a result of this ge-netic alteration, a reduced number or a reduced activity of LDL receptors specific for apoB-100 is found. Patients affected by the homozygous type show the highest degree of plasma cholesterol and suffer from coronary heart disease (CHD) at a young age. The end point of any therapeutic intervention in patients affected by FH or other forms of hyperlipoproteinemia is to lower the risk for acute vascular events, especially acute myocardial infarction. The efficacy of such interventions has been communicated in several clinical trials by use of different lipid-lowering drugs. 7 -8 Platelets from patients with FH type Ila hyperlipoproteinemia exhibit enhanced aggregation and secretory responses to a variety of physiological stimuli, 10 -12 which might be reduced by administration of certain lipid-lowering drugs like nicotinic acid or clofibrate. 13 It has also been shown that platelets from patients with type Ila hyperlipoproteinemia exhibit an increased cholesterol and phospholipid content. 14 Because increases in the cholesterol content are associated with platelet hypersensitivity to stimulation, these changes may provide a basis for the abnormalities of platelet function observed in the disease. A further action of LDL on platelet activation could be mediated by direct stimulation through LDL binding sites, which are known to be different from the classical apoB/E receptor. 215 - 17 In this study we systematically examined the binding, spec-ificity, and interrelations of lu In-LDL with washed human platelets derived from volunteers and patients with heterozygous FH before and during hypolipemic drug therapy (gemfibrozil alone or in combination with cholestyramine). The interrelations of '"In-labeled HDL with platelets from the same patients have already been reported. 18 
Methods

Lipoprotein Isolation and Characterization
During the course of the studies, lipoproteins were isolated from 56 blood donors. None of the volunteers had received any medication for at least 3 weeks before blood donation. Blood (60 mL) was always collected through siliconized needles into heparin-coated vials after an overnight fast. Neither pooled plasma nor pooled lipoproteins were used throughout the study. In all blood donors, routine plasmatic lipid concentrations were determined (cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides). Only blood of normolipemic volunteers was used for lipoprotein preparations.
Lipoproteins were prepared from the fresh plasma by isopycnic ultracentrifugation using potassium bromide for density adjustment as described previously. 19 Briefly, after an 18-hour ultracentrifugation (L5-75 ultracentrifuge, Beckman Instruments, Inc., Palo Alto, Calif.; 40.3 Ti rotor at 40,000 rpm and 10°C), the VLDL fraction was withdrawn, and the pellet was resuspended in potassium bromide solution at a density of 1.063 g/mL, i.e., and centrifuged against the density gradient for 18 hours at 40,000 rpm and 10°C. The supernatant (d= 1.019-1.063 g/mL) contained the LDL fraction. HDLs (d=1.063-1.21 g/mL) were isolated by further sequential ultracentrifugation (43,000 rpm; 44 hours; 10°C; KBr rf=1.210 g/mL), i.e., KBr (grams)=plasma volume (milliliters)x (1.210-1.063)x0.94(constant)/[l-(0.297-1.210)]
The lipoproteins were dialyzed against phosphate-buffered saline (PBS), pH 7.4, containing 0.1 mg/mL EDTA and stored at 4°C for not longer than 1 week. The total protein content of the lipoproteins was analyzed by the method of Lowry et al 20 and was used to determine LDL amounts for labeling. Lipoproteins were concentrated by ultrafiltration using Centrisart UF membranes (Sartorius, Gottingen, FRG). The apoprotein composition of each of the lipoprotein classes was assessed by radial immunodiffusion.
Radiolabeling
For each series of experiments, LDLs of one normolipemic subject were used for labeling with '"In. 21 -22 "'In was chosen in view of future in vivo studies in the same patients because its half-life (2.83 days) is sufficiently long to allow long-term imaging of atherosclerotic lesions. Briefly, to a microvial equipped with a magnetic stirrer, 1 mg LDL in 200 jtL PBS (pH 7.5), 20 fjL of 0.5 M NaHCO 3 , and 36 fig cyclic diethylenetriaminepentaacetic acid (DTPA) anhydride (Sigma Chemical Co., St. Louis, Mo.) in 9 fiL dry dimethyl sulfoxide (Merck, Darmstadt, FRG) were added. The mixture was slowly stirred for 1 hour and applied to a 5x40-mm Sephadex G50F column (Pharmacia, Uppsala, Sweden) equilibrated in metal-free acetate-buffered saline (ABS), pH 5.5. The column was eluted with ABS, and the protein fraction (240 fiL) was collected into a microvial. To this mixture, 600 ^Ci ['"In]Cl 3 in 40 fiL of 0.04 M HC1 was added with gentle mixing. After 1 hour at room temperature, the reaction mixture was applied onto a second ABS-equilibrated Sephadex G50F column. The '"In-labeled protein fraction (350 ^L) was collected and mixed with 1 mM DTPA in PBS to give 1 mL of the final product solution. The integrity of protein was tested by trichloroacetic acid (TCA) precipitation (10% TCA final concentration). The amount of radioactivity localized in the lipid moiety was 5-10% (of the total incorporated radioactivity) as estimated by extraction with chloroform/methanol. 23 Radiochemical purity was determined by 1) thinlayer chromatography (TLC) with silica gel plates (Merck) and an eluant composed of methanol:10% ammonium formate:0.5 M citric acid (20:20:10 [vol/ vol/vol]), 2) cellulose acetate electrophoresis with 0.05 M barbital buffer, pH 8.6, containing 1 mM EDTA and 1% human serum albumin at 300 V for 20 minutes, and 3) polyacrylamide gel electrophoresis (PAGE) with gradient gels (8-18%) and a gel buffer of 0.12 M tris(hydroxymethyl)aminomethane (Tris), 0.12 M acetate, and 0.1% sodium dodecyl sulfate, pH 6.4 (LKB/ Pharmacia, Uppsala, Sweden), at 50 mA/gel, 200-600 V for 60 minutes.
Binding Studies
Patients and healthy control subjects. Thirty-six patients (14 men and 22 women aged 19-62 years) with heterozygous FH (strong familial history with high values for total cholesterol, LDL cholesterol, and triglycerides, as well as reduced liver uptake of radiolabeled LDL in vivo [ Table 1 ]) and 15 healthy normolipemic volunteers (eight men and seven women aged 22-49 years) were studied.
All normolipemic control subjects were drug free for at least 3 weeks. None smoked or had any other known risk factor for the development of atherosclerosis. To examine individual variation of the binding data, eight healthy volunteers were investigated twice within 3 months.
FH patients taking drugs known to interfere with platelet function, lipid metabolism, or the prostaglandin system were excluded from the study. All patients were confirmed (by subjective judgment) to have been on a low-cholesterol diet for at least 6 months.
The effect of a 2-month "controlled-diet period" on LDL binding sites was studied in eight FH patients. For this period, each patient received a diet plan calculated for a daily cholesterol intake of <300 mg. Furthermore, the patients were required to complete a questionnaire that assessed their definite daily consumption in terms of eating and drinking. A trained dietary assistant monitored the questionnaire and calculated the total daily cholesterol intake.
To study the effect of a lipid-lowering medication in 10 patients, LDL binding sites were estimated before treatment and after 2 and 6 months of treatment with the clofibrate analogue gemfibrozil, either alone (450- Diagnosis of heterozygous familial hypercholesterolemia was based on typical familial history for raised LDL in at least one family member. In patients 4, 7, 9, 11, 12, 14, 15, 17, 19, 22, 23, 24, 25, 26, 30, 31, 35 , and 36, xanthomata were found. In patients 8-21, 24-31, and 34-36 in vivo LDL uptake by the liver was estimated and found to be reduced. Data from patients 32 and 33 were excluded from the statistical evaluation presented in Table 2 because of anamnesis of alcohol abuse. In patient 12, the value for LDL is not reported because the result (120 mg/dL) was most likely a laboratory failure. On this basis, all patients listed, except patients 1, 2, 12, 32, and 33, had definite familial hypercholesterolemia.
rug daily) or in combination with cholestyramine (8-16 g daily).
Platelet isolation and characterization. All blood processing was carried out in plastic ware at room temperature. In the morning after an overnight fast, venous blood (60 mL) was collected through siliconized needles into 3x20-mL plastic syringes containing acid-citratedextrose (3:7 [vol/vol] ). In preliminary experiments, platelets were isolated by differential centrifugation. Platelet-rich plasma was prepared by centrifugation (lOOg for 10 minutes). In a further centrifugation step (l,OOQf> for 25 minutes), a platelet pellet was obtained and was washed twice in buffer containing 0.9% NaCl, 50 mM Tris-HCl, and 2% Na-EDTA (20:1:2 [vol/vol/ vol], pH 7.2). The washed pellet was taken up in assay buffer containing 50 mM Tris-HCl, pH 7.5,5 mM CaCl 2 , and 5 mM MgCl 2 . Platelet counts were determined electronically and by counter flow.
The effectiveness of the washing procedure in removing autologous plasma proteins was assessed by adding m In-LDL to the platelet-rich plasma. On the basis of the recovery of radioactivity in the isolated platelet suspension, 6±1 ng LDL was present per 10 9 platelets. Residual binding of autologous LDL to washed platelets was also investigated directly with anti-apoB antiserum. Washed platelets (2xlO 7 ) were lysed in 2% sodium dodecyl sulfate buffer and electrophoresed on Pharmacia gradient gel (2-16%). After blotting onto nitrocellulose membranes, the blotted proteins were probed by anti-apoB antiserum (Behring AG, Vienna) and developed by peroxidase-conjugated anti-rabbit antibody and 4-chloro-l-naphthol. By this method, LDL protein is detectable in the range of 50-200 pg per band. No apoB was found by this method.
Platelet aggregation was studied in a Born-type aggregometer. 24 Platelets (2.5 xlOV/xL in 600 /xL) were aggregated with 1 /xM ADP (100 /xL). Prostaglandin (PG) I 2 (The Upjohn Co., Kalamazoo, Mich.) was used as an indicator for inhibition of platelet aggregation. The effect of labeled LDL and unlabeled LDL and HDL on platelet aggregation was determined by addition of various concentrations of the labeled and unlabeled lipoproteins 10 minutes before the induction of aggregation with ADP. The aggregation response was verified by the height (T max ) and slope (a) of the response curve.
Radio-TLC analysis was used for quantitative determination of [ Binding assays. To investigate ligand binding to platelets, direct binding experiments were carried out.
Incubations were done in duplicate. The within-assay variability was 3.9±0.9%; the between-assay variability was 6.2±1.0%. In initial experiments, the time course of association in binding was studied by incubating the platelets (5xlO 6 cells) with '"In-LDL (1.5 /xg protein per milliliter) in the absence (total binding) and presence (nonsaturable binding) of unlabeled LDL (100 /xg protein per milliliter) for 1-120 minutes. Dissociation of binding was induced by the addition of an excess amount of unlabeled LDL (100 fig protein per milliliter) at different time intervals (1-60 minutes) at equilibrium.
The influence of temperature on binding was studied in equilibrium experiments carried out at 4°, 15°, 22°, and 37°C.
For competition experiments, the cells were incubated at room temperature for 45 minutes with 5 /xg protein per milliliter "'In-LDL (925 cpm/ng protein) in the absence (total binding) and presence (nonsaturable binding) of increasing concentrations (0.1-500 /xg protein per milliliter) of unlabeled LDL or unlabeled HDL. To evaluate the specificity of '"In-LDL binding onto platelets, several unrelated proteins (albumin, fibrinogen, myoglobin, ovalbumin, soybean trypsin inhibitor, and transferrin) were also tested for their capacity to displace bound '"In-LDL by using a 25-50-fold molar excess of each unlabeled competitor protein.
In saturation experiments, the cells were incubated with increasing concentrations of "'In-LDL (0.1-70 /xg protein per milliliter) in the absence (total binding) and presence (nonsaturable binding) of unlabeled LDL (100 /xg protein per milliliter).
After incubation, the tubes were rapidly centrifuged (l,500g for 10 minutes at 4°C) to separate free from membrane-bound radioligand. After washing twice, the pellet was counted in a gamma counter for 1 minute.
Specific binding was determined as the difference of total and nonsaturable binding. In typical experiments, nonsaturable binding (determined in the presence of an excess of unlabeled LDL) amounted to <10% of total binding in the high-affinity ligand range: specific binding = total binding -nonsaturable binding = 100-(<10) = >90.
In the absence of platelets, the application of 30 /xg protein of '"In-LDL resulted in the recovery of less than 1 fig protein of "'In-LDL in the tip of the tube after centrifugation (<4%). This amount was identical for incubations of total and nonsaturable binding.
Analysis
Binding data were calculated according to Scatchard. 25 Values are presented as mean±SD. Statistical analysis was done by standard statistical tests including Student's t test, analysis of variance, and simple linear regression analysis at a confidence level of 95%.
Results
Human plasma LDL (d= 1.019-1.063 g/mL) was isolated by isopycnic gradient ultracentrifugation in potassium bromide and conjugated with DTPA chelator by reacting the bicyclic DTPA anhydride with LDL in a molar ratio of 50:1 (apoB-100, 500 kD). At this molar ratio of reactants, the average number of DTPA groups bound per LDL molecule amounted to 5.5±2.3. The LDL-DTPA conjugate was labeled with '"In in isolated radiochemical yields of 72±9% (range, 65-85%), resulting in a specific activity of 160-240 /xCi/mg LDL protein.
Labeled LDLs were routinely analyzed by TLC (Figure 1 ) and cellulose acetate electrophoresis (Figure 2) . '"In-DTPA-LDL remained at the starting point under the conditions chosen and contained typically <1% of '"In-DTPA and free '"In ion. On gradient gel PAGE, 123 I-LDL and '"In-DTPA-LDL displayed identical bands (silver staining) as compared with unlabeled LDL. 22 To determine the percentage of total radioactivity bound to the product, aliquots of "'In-LDL were added to unlabeled lipoprotein and analyzed by ultracentrifugation at a KBr density of 1.063 g/mL. The radioactivity found amounted to >96±2% in the lipoproteinspecific fraction, indicating that nearly all of the radioactivity was bound to a product with the density of native LDL; 96% of the radioactivity of '"In-LDL was precipitated with 10% (final concentration) TCA. As judged by electron microscopy, the washing method did not induce cell lysis or platelet aggregation in blood samples from volunteers or patients (Figure 3) . Retention of natural biological activity of lu In-labeled LDL was shown in aggregation experiments using the washed platelets. As isolated, platelets exhibited typical aggregation responses to ADP (T max , 56.5±6.1%; a, 65.2+4.3°; n = 10) and normal sensitivity to PGI 2 (half-
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In(DTPA)LDL599% FIGURE 2. In-LDL to percent '"In-LDL present in the incubation mixture, which reflects the same binding behavior of '"In-LDL and unlabeled LDL to platelets, as previously shown with liver cells. 18 To obtain information about the optimal conditions for the planned receptor studies with FH patients, the interaction of "'In-LDL with washed human platelets was assessed as a function of time and temperature. As shown in Figure 4 , "'In-LDL was bound to the washed platelets at 22°C, and the time course of the binding reaction gave a rapid increase of binding for approximately 5 minutes and reached an apparent equilibrium at 15 minutes. In the same experiment after a 60-minute incubation time, displacement of '"In-LDL by an excess of 100 fig protein per milliliter of unlabeled LDL could be achieved, indicating that 90% of the bound material was not incorporated under these conditions.
Binding of the '"In-labeled lipoprotein in the presence of an excess of 100 fig protein per milliliter nonlabeled lipoprotein was <10% of the total binding observed in the absence of nonlabeled lipoprotein. Approximately 7% of the total "'In-LDL present in the incubation medium was bound to the platelets.
The interactions were only slightly temperature dependent. At 22°C, binding of '"In-LDL at 45 minutes was 96% of that observed at 37°C; at 15°C, it was 92%; and at 4°C, it was 88%. In all subsequent experiments, lipoprotein binding was measured at 22°C, with a 45-minute incubation time to ensure equilibrium.
Unlabeled LDL and also HDL caused significant inhibition of "'In-LDL binding to washed human platelets ( Figure 5 one FH patient with a low binding capacity is shown in Figure 7 .
A significant correlation was found between lu In-LDL binding data and plasma lipid and lipoprotein concentrations. The linear regression analyses listed in Table 2 show that the higher the total plasma cholesterol, LDL cholesterol, and apoB concentrations and the lower the HDL cholesterol and apoA-I concentrations are, the lower are the numbers of LDL binding sites on human platelets and the higher are the K a and IC 50 values. These correlations were stronger within the FH group as compared with the volunteers.
A weak correlation between age and lipids and lipoproteins as well as LDL binding data was also found. With increasing age, the levels for cholesterol, LDL cholesterol, and apoB increased, and the binding capacity decreased.
The heterogeneous group of FH patients was divided into several subgroups to explore the higher variation observed among the FH patients investigated. No significant difference was found between men and women, hypertensive and normotensive subjects, and smokers and nonsmokers. However, compared with those patients without any risk factor other than hyperlipidemia, diabetic patients (B max , 452±144 ng protein of "'In-LDL per LDL, low density lipoprotein cholesterol; k, Constant; d, y intercept; B^,,, maximal binding capacity; chol, cholesterol; HDL, high density lipoprotein cholesterol; apo, apolipoprotein; K a , dissociation constant; IC50, halfmaximal inhibitory doses at half-maximal association.
FIGURE 6. Saturation curve (left panel) and corresponding Scatchardplot (right panel) for specific '"In-low density lipoprotein (LDL) binding to washed human platelets from a normolipemic volunteer. Each assay tube contained the indicated concentrations of'"In-LDL (925 cpm/ng protein). Specific binding was calculated by subtracting the amount of'"In-LDL bound in the presence of an excess of unlabeled LDL (100 fig protein/mL, nonsaturable binding) from that bound in its absence (total binding
Linear regression analyses are given for n =49 independent determinations in different subjects (familial hypercholesterolemia patients, n=34; volunteers, n = 15).
The correlations obtained for Bnj,, IQ, and IC50 values with plasma lipid and lipoprotein values were stronger within the familial hypercholesterolemia group as compared with the correlations within the volunteer group. By taking the data of patients and volunteers together, a clear correlation of plasma lipid and lipoprotein with binding data was observed. The effect of a 2-month controlled-diet period on LDL binding was studied in eight FH patients (Table 3) . With the exception of one patient (No. 21), a small increasing effect on LDL binding capacity of platelets was observed; however, no significance was found for the mean values.
Ten of the patients listed in Table 1 were treated with lipid-lowering drugs (gemfibrozil alone or in combination with cholestyramine) to investigate changes in platelet LDL binding capacity. The binding results (Table 4) were distinctly correlated with lowered plasma total cholesterol, LDL cholesterol, and apoB concentrations as well as with increased HDL cholesterol and apoA-I concentrations after a 2-and 6-month treatment period. In some patients, treatment raised ni In-LDL binding capacity by up to 300% of pretreatment value. On average, "'In-LDL binding sites increased from 470 ±307 to 948 ±650 after 2 treatment months (p<0.05) and to l,272±701 ng protein/10 9 platelets (p<0.01) after 6 treatment months. Although there was a tendency for a decrease in K A and IC 50 values during treatment in most patients, the average values for K A and IC50 did not change.
Discussion
The major cells involved in atherogenesis are endothelial cells, monocytes/macrophages, smooth muscle cells, and platelets. Numerous articles have reported the association of hyperlipemia with an enhanced platelet aggregation response and increased release of platelet metabolic products, indicating a more sensitized state to activating stimuli. 26 - 27 The specific binding of iodinelabeled LDL to platelets from healthy normolipemic subjects has been established. 215 -1727 - 29 In the present study, we investigated and compared the binding of in In-LDL onto platelets from healthy volunteers and patients with heterozygous FH. We provide further evidence for the existence of LDL binding sites expressed on human platelets in normolipidemia and hyperlipidemia. These sites also bind HDL but not other unrelated proteins.
TLC and cellulose acetate electrophoresis of ni In-LDL showed the absence of low-molecular-weight labeling products; repeated ultracentrifugation of "'In-LDL at d = 1.063 g/mL demonstrated unchanged density; and PAGE showed no degradation products of the protein moiety of labeled LDL. Aggregation experiments with platelets from healthy subjects revealed that 11 'In-LDL retained its biological activity. Electron microscopy as well as radio-TLC results from arachidonic acid metabolization showed that the washing and separating procedures did not damage or grossly activate the platelets. Furthermore, unlabeled LDL and "'In-LDL interacted with the platelets with the same apparent affinity. Equilibrium binding of '"In-LDL reached halfmaximal saturation at 6 ng LDL protein per milliliter, The same method that was used to characterize the binding of "'In-LDL to washed platelets isolated from normolipemic subjects was also applied in patients with heterozygous FH. As listed in Tables 1-4 , the number of LDL binding sites was significantly (p<0.001) lower for the patients as compared with volunteers. Additionally in patients, significantly (p<0.001) higher K,, and ICS0 values were found, indicating weaker binding of "'In-LDL to this lower number of binding sites as compared with the corresponding values of the same LDL for control platelets. Furthermore, the ICSo for HDL competing with "'In-LDL binding was also significantly higher in patients (43k17 versus 72k19 pg protein per milliliter in volunteers, p<0.001). The required concentration of HDL to reduce LDL binding by half was roughly doubled, as it was for LDL itself. It can be assumed that the binding behavior of LDL and HDL onto platelets from FH patients is affected in a similar way,'8 giving the possibility that the relation of LDL and HDL binding is the determining factor. Detailed investigation of the mutual competition of LDL and HDL, in binding and inhibition experiment^^^ suggested two different binding sites for LDL and HDL, on platelets, which are not independent from each other. As discussed previously,'s the binding of LDL and HDL should take place at different sites of the large glycoprotein complex (GPIIbnIIa), which has been identified as binding proteins for LDL and HDL in platelets. 17 The binding of one lipoprotein class to GPIIb/GPIIIa obviously induces structural alterations, with the consequence of decreasing the apparent affinity measured for one lipoprotein class in the presence of the other.
The greater variation of the binding parameters within the patient group might be a consequence of the fact that the patients were very heterogeneous with respect to the presence of additional risk factors (i.e., smoking, hypertension, and diabetes) CHDIPVD, sex, and age. In a more detailed analysis, we have subgrouped the patients' data and found that, whereas LDL binding was not significantly different for men and women, a weak correlation was found with age, indicating a decrease of binding sites and binding affinity with advancing age. As with HDL receptor expression,ls LDL binding sites were highest in patients without risk factors other than hyperlipemia. Significance was found for FH patients who had diabetes or manifested atherosclerosis. Indeed, there is evidence that in diabetes mellitus platelet reactivity is enhanced,30 and platelet microthrombi have been observed in diabetic microangiopathy. The lowest numbers of LDL binding sites were found in FH patients who smoked and who had manifested CHDIPVD. However, smoking alone had no effect on LDL binding capacity, whereas it significantly reduced HDL receptors in the same patients. 18 The lower number of binding sites for LDL on platelets of FH patients cannot be considered from the same point of view as the LDL receptors on fibroblasts5 and lympho~ytes,~ which are responsible in these and mainly in the liver cells9 for the regulation of cholesterol biosynthesis. In platelets, there is no biosynthesis of cholesterol, and the binding proteins for LDL on platelets are identified as the glycoproteins IIb and IIIa (GPIIbnIIa).17 GPIIbnIIa complex in the platelet membrane is a well-known fibrinogen receptor, playing a central role in the early stages of platelet activation.
In the case of platelet-LDL binding in patients, the lower number of binding sites could not be the reason for their hyperlipidemic disorders, as it is in the case of reduced apoBE receptors in FH patients, but is more likely to be a consequence of the hyperlipidemic state and the corresponding permanently high LDL concentration and/or modified LDL, which in turn might be connected to the sensitized state of the platelet. This point of view is supported by the reversibility of the decrease of binding sites after a period of lipid-lowering strategies (Table 4) , giving a good correlation of lowered plasma cholesterol concentration and increase in the LDL binding capacity of platelets.
The underlying cause for the lower number of LDL binding sites found on platelets of FH patients is not clear. First, hyperlipidemic states can influence the development of megakaryocytes,3l resulting in abnormal platelets. Whether or how much an altered platelet contributes to reduced LDL binding cannot be decided on the basis of investigations hitherto. Second, a shortterm influence of LDL on platelets can be concluded from all data also showing an in vitro influence of LDL (e.g., on platelet aggregation," thromboxane product10n,~l Ca2+32 and phosphatidyl inositide34 metabolism, and PGI, ~e n s i t i v i t y~~.~~.~~) , always yielding a platelet in a more sensitized state. Furthermore, platelets from patients with hyperlipoproteinemia also possess an increased cholesterol and membrane phospholipid content, which is associated with an increased platelet sensitivity to aggregating agent~.~o.l3.~~
The activation state of the FH platelets could be related to the lower number of binding sites for LDL in platelets from FH patients. This could mean that a portion of platelets exists in an advanced step of the activation procedure, after the LDL-mediated stimulation. If this is the case, the number of LDL binding sites of platelets should be dependent on the activation stage. However, it has to be said that, although FH platelets were more sensitive to ADP-induced aggregation, they did not spontaneously aggregate during performance of the receptor assay, excluding the possibility of a reduced accessibility of the platelet membranes that was due to aggregation of activated platelets.
Why lower numbers of LDL binding sites are associated with enhanced platelet aggregation response is unknown. Similarly, Jamieson's group35 has observed that platelets of patients with FH have a reduced number of thrombin receptors but show increased aggregation response. Jamieson hypothesized that platelet hyperresponsiveness in FH arises from an alteration in the coupling mechanisms between thrombin binding and response. Involvement of LDL in these coupling mechanisms could produce the sensitized platelet in hyperlipidemia. From this point of view, the atherogenic potential of LDL is delivered by two possible courses of action: 1) The high levels of circulating LDL are responsible for hypercholesterolemia in these patients, causing arterial injury and cholesterol accumulation in the arterial wall. 2) Direct interaction of LDL with platelets leads to increased platelet activation in vivo, which in turn potentiates the atherogenic process. Our finding of a correlation of the low numbers of LDL binding sites on platelets with actual plasma levels for apoB-100 and LDL cholesterol supports the hypothesis that highaffinity LDL binding is involved in the activation of platelets. The described technique may also be a useful tool for the clinical diagnosis and monitoring of efficacy of dietary and/or drug therapeutic interventions in humans.
